MYOS RENS Technology (MYOS) Receiving Somewhat Positive Media Coverage, Accern Reports

Press coverage about MYOS RENS Technology (NASDAQ:MYOS) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MYOS RENS Technology earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.6977346405469 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of MYOS RENS Technology (NASDAQ:MYOS) traded down $0.01 during trading hours on Friday, hitting $1.47. The stock had a trading volume of 66,100 shares, compared to its average volume of 242,000. MYOS RENS Technology has a twelve month low of $1.08 and a twelve month high of $6.98. The stock has a market capitalization of $9.39, a P/E ratio of -2.23 and a beta of 1.47.

MYOS RENS Technology (NASDAQ:MYOS) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter. MYOS RENS Technology had a negative net margin of 941.41% and a negative return on equity of 71.14%. The company had revenue of $0.16 million during the quarter.

In related news, CEO Joseph Mannello acquired 20,336 shares of MYOS RENS Technology stock in a transaction dated Thursday, December 21st. The shares were acquired at an average cost of $1.46 per share, for a total transaction of $29,690.56. Following the completion of the transaction, the chief executive officer now directly owns 274,765 shares of the company’s stock, valued at $401,156.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders bought 112,024 shares of company stock worth $151,529 over the last 90 days. Company insiders own 45.70% of the company’s stock.

WARNING: This report was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3127174/myos-rens-technology-myos-receiving-somewhat-positive-media-coverage-accern-reports.html.

About MYOS RENS Technology

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Insider Buying and Selling by Quarter for MYOS RENS Technology (NASDAQ:MYOS)

Receive News & Ratings for MYOS RENS Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.